Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: Clinical and preclinical data

Medicine and Dentistry

• ALK Inhibitor 58%
• Anaplastic Lymphoma Kinase 41%
• Therapeutic Procedure 25%
• Non Small Cell Lung Cancer 25%
• Patient 16%
• Enalapril Maleate 16%
• Bypass 16%
• Chemotherapy 16%
• Crizotinib 16%
• Gene 8%
• thought 8%
• Oncogene 8%
• Alectinib 8%
• Epidermal Growth Factor Receptor 8%
• Hsp90 Inhibitor 8%
• Ceritinib 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Anaplastic Lymphoma Kinase Inhibitor 58%
• Anaplastic Lymphoma Kinase 41%
• Non Small Cell Lung Cancer 25%
• Enalapril Maleate 16%
• Crizotinib 16%
• Alectinib 8%
• Heat Shock Protein 90 Inhibitor 8%
• Ceritinib 8%

Biochemistry, Genetics and Molecular Biology

• Anaplastic Lymphoma Kinase 100%
• Crizotinib 16%
• Nested Gene 8%
• Electric Potential 8%
• thought 8%
• Mutation 8%
• Oncogene 8%
• KRAS 8%
• Ceritinib 8%
• Heat Shock Protein 90 Inhibitor 8%